Gilead licenses three Vir dual-masked T-cell engager programs

Gilead Sciences has entered an oncology partnership with Vir Biotechnology to license three T-cell engager candidates built on Vir’s dual-masked PRO-XTEN platform, according to Fierce Biotech. The agreement centers on candidates against solid tumor-associated antigens.

Division of responsibilities

Vir will lead discovery, design and optimization for the three T-cell engager candidates. Gilead has exclusive rights to nominate candidates and will take responsibility for subsequent development, manufacturing and commercialization, Fierce Biotech reported.

The companies have selected targets for all three programs, Vir CEO Marianne De Backer told Fierce Biotech, while declining to further characterize the proposed indications.

Vir’s PRO-XTEN approach masks both the tumor-associated binding domain and the T-cell binding domain of a T-cell engager. Fierce Biotech reported that the molecule remains inactive until tumor-specific proteases cleave the masks at the tumor.

Financial structure and oncology context

Under the agreement, Vir will receive $90 million upfront, comprising $65 million in cash and a $25 million equity investment priced at a 30% premium, Fierce Biotech said. The deal also includes $45 million in near-term preclinical milestones and up to $1.74 billion in additional development, regulatory and commercial milestones, plus tiered high single-digit to low double-digit royalties on sales.

Fierce Biotech characterized the arrangement as a potential $1.9 billion deal. The publisher reported that Vir’s platform had previously supported a potential $1.7 billion partnership with Astellas formed in February.

What sales professionals should watch

• Gilead is adding externally discovered T-cell engager programs to its oncology portfolio.
• Vir retains work in discovery, design and optimization, while Gilead assumes later-stage development, manufacturing and commercialization responsibilities.
• The agreement focuses on solid tumor-associated antigens, an area where Fierce Biotech noted T-cell engager use has been limited by toxicity.

For pharmaceutical and biotech commercial professionals, the partnership highlights how platform licensors and larger oncology organizations can divide responsibilities across the path from candidate design to commercialization.